ASH 2021 | CAR-T cell therapies in T-cell lymphoma and leukemia
The use of chimeric antigen receptor (CAR) T-cell therapy in T-cell malignancies have been previously limited due to shared antigens and subsequent fratricide. LaQuisa Hill, MD, Texas Children’s Hospital, Houston Methodist Hospital, Houston, TX, provides an overview of the developments made within the field. Anti-CD5 and -CD7 CAR T-cell therapies have proven to be promising treatments for patients with T-cell acute lymphoblastic leukemia (T-ALL) and T-lymphoblastic lymphoma (T-LBL). Anti-CD30 therapies have additionally demonstrated efficacy in patients with peripheral T-cell lymphoma (PTCL) and a favorable safety profile with fewer cases of cytokine release syndrome and neurotoxicity. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
